Decontamination chemistry
specific products, but would emphasise principles: consistency of delivery, traceability of performance, and alignment with clinical workflows. Controlled generation systems align naturally with this perspective, as they embed performance parameters into the delivery mechanism itself. Importantly, adopting such approaches does not imply abandoning existing standards or chemistries. Instead, it reflects
Features
Feature / benefit desired from chlorine dioxide
Broad-spectrum antimicrobial activity (including biofilm disruption)
a maturation of how those chemistries are deployed.
Case illustration: controlled oxidation platforms in practice Several technology platforms are now exploring controlled oxidation approaches across healthcare and related sectors. One example, developed originally under public sector
Constraints enabled
Why unavailable? (“as-is” ClO2
- cannot reliably perform)
Unreliable because prepared ClO₂ degrades in storage and delivered concentration is variable, reducing efficacy and biofilm penetration.
Predictable potency & stability (consistent concentration at point of use)
Safe, low-risk handling for staff
Prepared solutions degrade during storage/transport; shelf-life variability produces inconsistent dosing.
Use of concentrated stocks and unstable intermediates requires extensive PPE, controls and training, raising safety and operational burden.
Material compatibility with sensitive devices
High or uncontrolled oxidant exposures and variable chemistry can damage materials or be incompatible with device reprocessing.
Traceability & repeatability (validation & QA)
Bulk preparation + unpredictable degradation make traceable, repeatable performance difficult to guarantee or validate.
Improved throughput & lower rework
Targeted delivery to lumened devices (endoscopes)
Operational resilience & system integration
Preparation delays, under-dosing and rework reduce throughput in high-volume sterile services.
Difficulty delivering the right concentration/time/ target within lumens leads to persistent biofilms despite guideline compliance.
Decontamination often treated as downstream task; chemistries are not integrated with workflow or governance, limiting system optimisation.
Low environmental persistence and reduced by-products
Regulatory alignment & easier validation
Bulk handling and uncontrolled reactions risk residues or undesirable by-products and regulatory concern.
Variability in manufacture/ storage complicates regulatory validation and approvals for routine healthcare use.
Table 1. Taking chlorine dioxide from industrial chemical to medical device 68
www.clinicalservicesjournal.com I November 2026
research programmes, uses a solid redox medium to convert a dilute precursor solution into an active oxidant at the point of use. The system is designed to produce consistent aqueous output without stored gas or unstable intermediates. While such platforms remain subject to
appropriate regulatory pathways, depending on application, they illustrate how long-standing
Re-engineered capabilities
Benefits enabled by re-engineering (attributes & benefits now available)
On-demand generation of defined aqueous ClO₂ concentrations at point-of-use ensures fresh, effective chemistry and improved biofilm-disrupting exposure.
Stable precursor + controlled point-of-use conversion avoids bulk storage of active oxidant; system parameters define output concentration and consistency.
Limits need for high-concentration storage and hazardous concentrates; on-demand generation and lack of stored gas/unstable intermediates lower exposure and operator burden.
Reaction management and defined output concentrations reduce exposure to destructive conditions; better ability to design chemistry for compatibility.
Chemistry becomes a function of system parameters (embedded control), enabling traceability, repeatable outputs, and easier validation.
Predictable output and consistent dosing reduce rework and delays; supports more predictable device turnaround and higher throughput.
Point-of-use, controlled delivery ensures the right concentration and contact time at the target, improving penetration and biofilm control.
Embeds chemical generation into workflows and governance; supports national/organisational strategies that prioritise consistency, traceability and workforce safety.
On-demand production of non-persistent oxidant at controlled doses minimises residual chemistry and environmental/occupational exposure.
Defined system parameters and controlled generation reframe performance as an engineering
property, simplifying pathways for validation (still subject to regulatory review).
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71